drugset / Trial / NCT00318474
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
RandomizedParallel-groupDouble-blindTreatment
Summary
IgA nephropathy (IgAN) is the most common type of glomerulonephritis worldwide. 15-40% of individuals diagnosed with IgAN, including children, will eventually progress to chronic renal insufficiency (CRI) and end stage renal disease (ESRD). The study is to evaluate the safety and benefits of MMF in patients with IgAN who have been pre-treated (and continue to be treated) with angiotensin converting enzyme inhibitors (ACEi) and fish oil supplements (FOS).
Timeline
- Start
- 2002-01
- Primary completion
- 2008-03
- Completion
- 2010-03
Publications
- Alladin A, Hahn D, Hodson EM, Ravani P, Pfister K, Quinn RR, Samuel SM. Immunosuppressive therapy for IgA nephropathy in children. Cochrane Database Syst Rev. 2024 Jun 12;6(6):CD015060. doi: 10.1002/14651858.CD015060.pub2.
- Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mycophenolate Mofetil | Small molecule | 25 mg/kg | Oral |
| Comparator | Mycophenolate Mofetil | Small molecule | 36 mg/kg | Oral |
| Comparator | Mycophenolate Mofetil | Small molecule | 1 g | Oral |
| Comparator | FOS | Unknown | — | — |